Skip to main content
. 2018 Sep 11;13(9):e0203890. doi: 10.1371/journal.pone.0203890

Fig 2. Prevalence of polypharmacy by age, HIV status, and visit.

Fig 2

(A) Polypharmacy prevalence among HIV-positive and -negative participants 50 years and older. (B) Polypharmacy prevalence among HIV-positive and -negative participants younger than 50 years old.